News

The International Association for the Study of Lung Cancer (IASLC) will hold a press conference on Tuesday, Sept. 8, 2015 at 9:45 a.m. MDT to reveal findings from key abstracts detailing advances in lung cancer study and research. Full presentations of these abstracts and other lung cancer study advancements will take place throughout the 16th World Conference on Lung Cancer (WCLC).

DENVER, Colo. — Adding the angiogenesis inhibitor bevacizumab to standard treatment for malignant pleural mesothelioma (MPM) increases life expectancy without severe toxicity, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). The French multicenter randomized phase 3 trial data was presented by Dr. Arnaud Scherpereel, Head of the Pulmonary and Thoracic Oncology Department and Professor at the University Hospital (CHU) of Lille, France.

DENVER, Colo. — Two Phase III studies with anamorelin found that the medication effectively combats wasting and increases body weight and lean body mass in certain lung cancer patients. Results from the ROMANA 1 and ROMANA 2 Phase III trial of anamorelin were presented today in Denver, Colo. at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

DENVER, Colo. — Every hour lost to the cancer drug regulatory process costs 29 life-years lost in the U.S. and 260 life-years worldwide, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). Dr. David Stewart, Head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, presented data on how the regulatory process of new therapies slows progress by increasing drug developments costs and by producing speed bumps that delay approval of useful drugs. This process also increases resources required to document that other agents are ineffective.

DENVER, Colo. – “We all share one goal: conquering the lung and thoracic cancers that account for nearly a third of all cancer deaths worldwide – more than breast, prostate and colon cancers combined,” said Dr. Fred R. Hirsch, CEO of the International Association for the Study of Lung Cancer (IASLC), professor in Medicine and Pathology at the University of Colorado and Congress President. Hirsch opened the first daily press briefing with an overview of the 16th World Conference on Lung Cancer (WCLC).

The International Association for the Study of Lung Cancer (IASLC) will hold a press conference on Monday, Sept. 7, 2015 at 9:45 a.m. MDT to reveal findings from key abstracts detailing advances in lung cancer study and research. Full presentations of these abstracts and other lung cancer study advancements will take place throughout the 16th World Conference on Lung Cancer (WCLC).

Pages